Cell therapy remains the most promising approach against ischemic heart injury. However, the poor survival of engrafted stem cells in the ischemic environment limits their therapeutic efficacy for cardiac repair after myocardial infarction. CTRP9 (C1q/tumor necrosis factor-related protein-9) is a novel prosurvival cardiokine with significantly downregulated expression after myocardial infarction. Here we tested a hypothesis that CTRP9 might be a cardiokine required for a healthy microenvironment promoting implanted stem cell survival and cardioprotection.
M
yocardial infarction results in compromised myocardial function and heart failure because of acute and chronic loss of cardiomyocytes. 1 Because adult mammalian hearts have limited regenerative capacity, stem cell therapy is a potential strategy regenerating myocardium. 2 Multiple preclinical studies utilizing mesenchymal stem cells (MSCs) have been conducted, demonstrating favorable impact on left ventricle remodeling. [3] [4] [5] However, the favorable results observed in animal studies have not been fully translated to patients with myocardial infarction (MI) and heart failure largely because of the poor survival of engrafted MSCs in the ischemic environment. 6 Overcoming this limitation by either promoting MSCs survival or improving the local environment may enhance the effectiveness of cell therapy for MI. 7 The cellular secretome influences the local microenvironment, controlling disease development. The secretomes produced by the heart, collectively known as cardiokines, are increasingly recognized as essential regulators of cardiac physiology and pathology. The C1q/tumor necrosis factor-related proteins (CTRPs) are a protein family consisting of 15 (CTRP1-CTRP15) newly identified adiponectin paralogs. 8 We have previously demonstrated that CTRP9 is not a typical adipokine and actually functions as a cardiokine. 9 CTRP9 is highly expressed in the adult heart. The globular domain isoform of CTRP9 (gCTRP9) is generated via proteolytic cleavage of full-length CTRP9 (fCTRP9) in cardiac tissue and functions as the active cardioprotective isoform. 9, 10 A recent study confirmed our original finding and identified the heart as the organ expressing CTRP9 to the greatest degree, exceeding adipose tissue levels (where CTRP9 was originally discovered). 11 It has been demonstrated that CTRP9 is a potent cardioprotective cardiokine; gC-TRP9 supplementation protects the heart from ischemic injury and attenuates adverse cardiac remodeling after ischemic myocardial infarction. [12] [13] [14] Moreover, several recent studies have demonstrated significantly reduced plasma CTRP9 levels, as well as myocardial CTRP9 (both mRNA and protein) expression levels, after MI. 12, 14 However, whether reduced cardiac CTRP9 expression may affect the microenvironment of the infarcted heart, adversely affecting the fate of engrafted stem cells, has never been studied.
Thus, the aims of this study were to determine whether cardiokine CTRP9 regulates the microenvironment of infarcted heart, thus controlling the fate of engrafted adipose-derived mesenchymal stem cells (ADSCs) and their cardiac protective effect, and if so, to determine the underlying mechanisms, including the specific receptor(s) and intracellular signaling pathways involved.
METHODS ADSCs Isolation, Identification, and In Vitro Studies
ADSCs were isolated from male enhanced green fluorescent protein transgenic mice mice (The Jackson Laboratory) or littermate C57BL/6J control mice as previously reported ( Figure IA in the online-only Data Supplement). 15 Cells were cultured in Dulbecco's Modified Eagle Medium-F12-10% FBS. Surface marker expression was evaluated by flow cytometry (BD LSRFortessa). For flow cytometry, 2×10 6 ADSCs were stained with the following fluorescent antibodies: CD105 (BD Biosciences), CD31 (BD Biosciences), CD90.2 (BD Biosciences), CD45 (BD Biosciences), and their phycoerythrin isotype control. ADSCs multilineage potential was evaluated by adipogenic and osteogenic differentiation. ADSCs population viability was determined over time via a Cell Counting Kit-8 (Sigma). For migration assay, wound healing and Transwell studies were performed. The conditioned medium (CM) of ADSCs was collected via a modified method 16 : passage 2 ADSCs were grown to 90% confluence in 6-well dishes and incubated for 24 hours with gCTRP9 (2.0µg/mL) or vehicle. The culture medium was washed and replaced by serumfree Dulbecco's Modified Eagle Medium/F12 medium. After another 24 hours, CM was collected, used for cardiomyocyte treatment, or stored at -80°C for future use.
Clinical Perspective
What Is New?
• This study demonstrates for the first time that C1q/ tumor necrosis factor-related protein-9 (CTRP9) is an important cardiokine governing the local environment in an infarcted heart that determines the fate of implanted cells.
• This study provides the first evidence that N-cadherin is the receptor-mediating CTRP9-initiated signaling in adipose-derived mesenchymal stem cells, filling a significant gap in the field concerning this important cardiokine.
• Extracellular regulated protein kinases1/2-matrix metallopeptidase 9 and extracellular regulated protein kinases1/2-nuclear factor erythroid-derived 2-like 2 signaling are responsible for CTRP9-induced adipose-derived mesenchymal stem cell proliferation/migration and antioxidant/antiapoptotic effects, respectively.
What Are the Clinical Implications?
• Strategies improving the local microenvironment in the ischemic heart may have great potential to enhance cell therapy efficacy against ischemic heart injury.
• The combination therapy of CTRP9 with mesenchymal stem cells may be a novel strategy protecting against cardiac injury after myocardial infarction.
• Targeting CTRP9/N-cadherin signaling in mesenchymal stem cells may improve the efficacy of cell therapy.
Animal Study Protocol
All experiments were performed in adherence to the National 
Coimmunoprecipitation, Western Blot Analysis, Immunohistochemistry, and Quantitative PCR
For coimmunoprecipitation, ADSCs were treated with hisgCTRP9, his-fCTRP9, flag-fCTRP9, or vehicle. Cells were washed once with PBS and lysed with cold 1×lysis buffer supplemented with a protease inhibitor cocktail. For an in-tube assay, human recombinant CTRP9 (Novus) and human recombinant N-cadherin (LSBio) were mixed in cold 1×lysis buffer. The samples were immunoprecipitated with anti-CTRP9 antibody (provided by Dr. G. William Wong) or antiflag M2 (Sigma) antibody.
For Western blot, total proteins were isolated from cells or heart tissues. Nuclear and cytoplasmic proteins were prepared by a Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher Scientific). Protein samples (including samples immunoprecipitated with anti-CTRP9 antibody) were separated via gel electrophoresis, transferred to a polyvinylidene fluoride membrane, and blocked with 5% milk for 1 hour. The membrane was incubated overnight with primary antibodies (4°C). The membranes were then incubated with secondary horseradish peroxidase-conjugated antimouse antibody or antirabbit antibody at room temperature for 2 hours and exposed to enhanced chemiluminescent substrate (Thermo Fisher Scientific). Western blot results were quantified by densitometry (Image Laboratory).
For immunohistochemistry, wax blocks were cut into 5-μm-thick sections and mounted on glass slides for staining. Slides were deparrafinized and subjected to antigen retrieval in hot citric acid buffer. After cooling, slides were permeabilized with 0.2% Triton-100 for 15 minutes and blocked with 1% BSA in PBS for 2 hours. Slides were incubated overnight with primary antibodies (4°C). Primary antibodies were visualized with secondary antibodies conjugated with Alexa Fluor 488 or Rhodamine (ThermoFisher Scientific). Nuclei in both cells and embedded tissues were stained with 4',6-diamidino-2-phenylindole (Vector Laboratories, H-1200). Micrographs of all immunostains were acquired via an Olympus BX51 
Statistical Analysis
Data are reported as mean±SEM. The Kaplan-Meier survival curves were analyzed by a Gehan-Breslow-Wilcoxon test. For analysis of differences between 2 groups, the unpaired Student t test was performed. For multiple groups, 1-way ANOVA was carried out followed by a Bonferroni post hoc test. For multiple groups over time or for testing the interaction of CTRP9/ADSC therapy on heart function after MI, a 2-way ANOVA was performed, followed by a Bonferroni post hoc test. P values <0.05 were considered significant. In this study, n is the number of animals or cell cultures tested.
RESULTS

CTRP9 and ADSCs Exerted Synergistic Protection Against Cardiac Injury After MI
The passage 2 ADSCs were tested for surface marker expression and differentiation potential. Of these 154 MI mice, 59 died at various time points during follow-up ( Figure 1A ). Administration of ADSC or gCTRP9 alone failed to significantly improve the survival rate. However, a combination of ADSC and gCTRP9 improved survival significantly more than vehicle or ADSCs alone. Autopsy demonstrated that LV rupture was the main reason for death after MI in this mouse MI model, consistent with our survival data. A combination gC-TRP9/ADSC treatment resulted in a sharp reduction of LV rupture, although the difference was not statistically significant ( Figure IVA in the online-only Data Supplement). No significant difference in heart rate was observed between the vehicle-treated and ADSC, gCTRP9, or combination ADSC/gCTRP9 treatment groups ( Figure IVB in the online-only Data Supplement). However, the gCTRP9/ ADSC combination increased LV ejection fraction significantly more than ADSCs or gCTRP9 treatment alone, and a positive interaction between gCTRP9 and ADSC was observed for this most important cardiac function measurement (P for interactions=0.0096) ( Figure 1B and C). The gCTRP9/ADSC combination also increased maximal values (+dP/dt max ) and minimum values (-dP/dt min ) of the instantaneous first derivative of LV pressure significantly more than ADSCs or gCTRP9 treatment alone ( Figure 1D -F, Figure IVC in the online-only Data Supplement), although a statistically significant positive interaction was not reached (P for interactions>0.05). Taken together, these results provide clear evidence that the . I, Heart weight-to-body weight ratio (HW/BW). J, Lung weight-to-body weight ratio (LW/BW) (n=10-18). K and L, Representative images and quantification of TUNEL-positive cardiomyocytes in infarct border zone 3 days after MI. Cell nuclei were stained with 4'-6-diamidino-2-phenylindole (DAPI; blue) (n=6). Data are mean±SEM. *P<0.05; **P<0.01; ns, not significant. Survival curves were analyzed by Gehan-Breslow-Wilcoxon test. LVEF and ±dp/dt were analyzed with 2-way ANOVA followed by a Bonferroni post hoc test. Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. ADSCs indicates adipose-derived mesenchymal stem cells; AutoFluo, autofluorescence; CTRP9, C1q/tumor necrosis factorrelated protein-9; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; LV, left ventricular; MI, myocardial infarction; and TUNEL, transferase-mediated dUTP nick-end labeling.
ADSC/CTRP9 combination reduces rupture-related death and significantly protects the ischemic heart against cardiac dysfunction after MI in a synergistic fashion.
CTRP9 Treatment Atop ADSCs Implantation Significantly Reduced Fibrosis and Cardiomyocyte Apoptosis
Masson's trichrome staining of the transverse and coronal plane revealed that the cardiac size and myocardial fibrotic area were slightly reduced by ADSCs transplantation but were significantly reduced by gCTRP9 administration compared with MI+vehicle ( Figure 1G and H, Figure IVD in the online-only Data Supplement). Consistent with cardiac function data, the gCTRP9/ADSCs combination reduced the fibrotic area significantly more than ADSCs or gCTRP9 treatment alone (P<0.01 versus MI+ADSC+vehicle and MI+gCTRP9). Although a trend toward better protection was observed, differences in heart weight ( Figure 1I ) and lung weight ( Figure 1J ) were not statistically significant between the gCTRP9 alone and the gCTRP9+ADSC groups. TUNEL assay (infarct border zone 3 days after MI; Figure 1K and L) demonstrated that ADSCs did not significantly reduce cardiomyocyte apoptosis (P>0.05 versus MI+vehicle). However, gCTRP9/ ADSCs combination reduced cardiomyocyte apoptosis to an extent exceeding gCTRP9 alone (P<0.05) and markedly surpassing ADSCs treatment alone (P<0.01). Together these data suggest that gCTRP9 and ADSCs combination treatment significantly attenuated fibrosis and apoptosis after MI (the 2 most important pathological alterations during remodeling after MI), contributing to their synergistic cardioprotection against ischemic cardiac injury.
Myocardial CTRP9 Protein Level Is a Critical Factor Determining ADSCs Engraftment Rate
To investigate the effects of myocardial CTRP9 on engrafted ADSCs survival, we used both gain-and lossof-function approaches. ADSCs retention 1, 3, 7, and 14 days after MI in CTRP9 knockout (KO) mice and wild-type littermates treated with CTRP9 or vehicle was determined. Transplanted cells were tracked in myocardial tissues via immunofluorescence staining for GFP expression. The engraftment rate was calcu- A, Representative images of EGFP ADSCs in hearts 1 and 3 days after MI. Heart tissue was immunostained for GFP (green), DAPI (blue), and troponin T (red). B, Quantification of EGFP ADSCs in the peri-infarct area was determined by the number of GFPpositive cells per total nuclei (n=20 from 4 mice). C, ADSCs engraftment was quantified as the number of GFP-positive cells per 100 heart cells in apex region (n=4 mice). Data are mean±SEM. *P<0.05 vs. wild-type (WT) MI+ADSC+vehicle. Statistical significance was determined with 2-way ANOVA followed by Bonferroni post hoc test. ADSCs indicates adipose-derived mesenchymal stem cells; CTRP9, C1q/tumor necrosis factor-related protein-9; DAPI, 4',6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; KO, knockout; and MI, myocardial infarction. lated via quantitative PCR measurements of GFP DNA. Clusters of ADSCs were observed in the border zone of ischemia 1 day after transplantation (Figure 2A and B). Compared with wild-type, markedly fewer GFP + cells were present in CTRP9KO hearts 3 days after MI. PCR results demonstrated that the engraftment/survival rate of ADSCs in the CTRP9KO group was significantly decreased compared with wild-type mice ( Figure 2C ). It is important to note that the gCTRP9 treatment significantly prolonged cell retention/survival in the infarct border zone (Figure 2A-C) . These results suggest that CTRP9 promotes the survival of implanted ADSCs and protects the ischemic heart, and that decreased myocardial CTRP9 contributes to low ADSCs engraftment in the infarcted heart.
CTRP9 Promoted ADSCs Proliferation, Migration, and Protected ADSCs From Hydrogen Peroxide-Induced Cell Death
To determine whether CTRP9 directly or indirectly regulates ADSCs function, we examined the differentiation, proliferation, migration, and cell death of ADSCs treated with or without gCTRP9 in vitro. Real-time PCR demonstrated that CTRP9 failed to affect cardiogenic, vasculogenic, or fibrogenic differentiation of ADSCs after 7 A, ADSCs proliferation curves (n=12; gCTRP9: 2 µg/mL). **P<0.01 vs. vehicle at indicated time. Statistical significance was determined with 2-way ANOVA followed by Bonferroni post hoc test. B and C, Wound healing assay and Matrigel precoated Transwell assay were performed 24 hours after gCTRP9 (2 µg/mL) or vehicle treatment (n=6). **P<0.01 vs. vehicle. Statistical significance was determined with unpaired Student t test. D through G, ADSCs apoptosis was determined by TUNEL staining, cleaved caspase-3 expression, and caspase-3 activity (n=6). H, ADSCs death was determined by LDH release (n=12; gCTRP9: 2µg/mL, 24 hours; H 2 O 2 : 200µM, 6 hours). Data are mean±SEM. **P<0.01 vs. control; # P<0.05 vs. H 2 O 2 +vehicle. Statistical significance was determined with 1-way ANOVA followed by Bonferroni post hoc test. ADSCs indicates adipose-derived mesenchymal stem cells; CTRP9, C1q/tumor necrosis factor-related protein-9; DAPI, 4'-6-diamidino-2-phenylindole; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; LDH, lactic dehydrogenase; O.D., optical density; and TUNEL, transferase-mediated dUTP nick-end labeling.
days of coculture with neonatal mouse ventricular cardiomyocytes (Figure V in the online-only Data Supplement). However, the Cell Counting Kit-8 assay demonstrated that, compared with vehicle, gCTRP9 increased ADSCs proliferation after 48 hours of treatment (Figure 3A) . Wound healing and matrigel-coated Transwell assays demonstrated that ADSCs exhibited a markedly enhanced migratory capacity after 24 hours of gCTRP9 treatment ( Figure 3B and C). Treatment of ADSCs with H 2 O 2 increased lactic dehydrogenase release and cleaved caspase-3 expression, caspase-3 activity, and TUNEL-positive nuclei. gCTRP9 treatment significantly attenuated all these markers of apoptosis and necrosis ( Figure 3D-H) .
These in vitro results demonstrate that CTRP9 directly promotes ADSCs proliferation, migration, and survival.
CTRP9 Increased Matrix Metallopeptidase 9 (MMP-9) and Antioxidant Protein Expression in ADSCs via ERK1/2 Activation
To identify the molecular mechanisms underlying the effects of CTRP9 on ADSCs proliferation, migration, and survival, we used quantitative PCR to analyze mRNA levels in ADSCs with or without gCTRP9 treatment; 66 mRNAs involving proliferation, migration, death, paracrine function, angiogenesis, antioxidation, mitochondrial function, pluripotency, cardiogenic differentiation, and endothelial differentiation were tested. The gCTRP9-treated ADSCs profile exhibited significantly increased expression of genes controlling migration and antioxidation ( Figure 4A ). Seven genes were increased by gCTRP9 >2-fold ( Figure 4B ). Among them, Western blot analysis confirmed that gCTRP9 significantly increased protein expression of 4 antioxidants, including manganese superoxide dismutase 2 (Sod-2), extracellular superoxide dismutase 3 (Sod-3), hemeoxygenase 1 (HO-1), and peroxiredoxin 1 (Prdx1) (Figure 4C and D). Moreover, both Western blot and In-gel zymography showed that CTRP9 significantly increased MMP-9 protein expression and activity in ADSCs ( Figure 4C and D, Figure VIA -C in the online-only Data Supplement).
To identify the upstream signaling molecules leading to MMP-9 and antioxidant protein expression, the effect of CTRP9 on several kinases known to regulate cellular proliferation and survival was determined. The 15-minute gCTRP9 treatment significantly increased ERK1/2 phosphorylation ( Figure 4E and F) . However, signaling pathways (such as AMP-activated protein kinase and Akt) activated by CTRP9 in other cell types were not activated in ADSCs (Figure 4E and F) . To identify a cause-effect relationship between ERK1/2 activation and MMP-9/antioxidant protein expression after CTRP9 treatment, we administered U0126 (an ERK1/2 activation inhibitor, 10 µM) 2 hours before gCTRP9 treatment.
U0126 blocked gCTRP9-induced upregulation of phosphorylated ERK1/2 (Figure VII in the online-only Data Supplement). It is important to note that gCTRP9-induced upregulation of MMP-9 and antioxidant proteins was completely blocked by U0126 ( Figure 4G and H).
ERK1/2-MMP-9 and ERK1/2-Nuclear Factor Erythroid-Derived 2-Like 2 Signaling Pathways Are Respectively Responsible for CTRP9-Induced ADSCs Proliferation/Migration and Antioxidant/ Antiapoptotic Effects MMP-9 is the most significantly upregulated protein among all proteins regulated by CTRP9 (>30 fold mRNA level and >4 fold protein level). To determine whether the proliferation/migration and antioxidant/antiapoptotic effects of CTRP9 are regulated by ERK1/2-MMP-9 signaling, ADSCs were treated with ERK1/2 activation inhibitor or MMP-9-blocking antibody before CTRP9 administration. Wound healing and matrigel-coated Transwell assays demonstrated that both U0126 and the MMP-9-blocking antibody attenuated gCTRP9-enhanced migratory capacity ( Figure 5A and B) . The Cell Counting Kit-8 assay revealed that both U0126 and MMP-9-blocking antibody inhibited gCTRP9-induced ADSCs proliferation ( Figure 5C ). It is interesting to note that the antiapoptotic effect of CTRP9 was abolished by the ERK1/2 activation inhibitor but not by the MMP-9-blocking antibody ( Figure 5D and E).
Nrf2 defends against oxidative stress at the cellular level. 19 The expression of Sod-2, Sod-3, HO-1, and Prdx1 is regulated by Nrf2.
20,21 Therefore, we assessed nuclear Nrf2 levels to determine whether the increase of these proteins resulted from the stabilization of the Nrf2 protein. As determined by immunostaining and protein expression in nuclear extracts, CTRP9 (2 µg/mL for 24 hours) increased the nuclear Nrf2 level in ADSCs ( Figure 6A and B) . Nrf2 activation by CTRP9 was also completely abolished by ERK1/2 activation inhibitor ( Figure 6C ), suggesting that Nrf2 is downstream of ERK1/2 in mediating the actions of CTRP9.
To establish a causative relationship between Nrf2 activation and antioxidant protein expression, Nrf2 expression was genetically inhibited by short-interfering RNA (siRNA) ( Figure VIII in the online-only Data Supplement). Nrf2 inhibition blocked CTRP9-induced antioxidant protein expression ( Figure 6D and E) . Moreover, Nrf2 knockdown virtually abolished the protective effects of CTRP9 against H 2 O 2 -induced ADSCs apoptosis and necrosis ( Figure 6F ). Collectively, these data demonstrate that the proliferation/migration effect of CTRP9 is mediated by ERK1/2-MMP-9 signaling, whereas the antiapoptotic and cell survival effects of CTRP9 are mediated by the ERK1/2-Nrf2 pathway activation.
N-Cadherin Is a Novel CTRP9 Receptor Mediating CTRP9 Effect in ADSCs
Several studies reported that the adiponectin receptor 1 (AdipoR1) contributes to the cardioprotective and vasculoprotective actions of CTRP9. 12, 14, 22 To analyze the involvement of AdipoR1 in the actions of CTRP9 on ADSCs, we isolated ADSCs from the AdipoR1 KO mice. To our surprise, the effect of CTRP9 on ADSCs proliferation, migration, cell survival, and antioxidant effect was fully intact in AdipoR1 KO ADSCs ( Figure IX in the online-only Data Supplement). Moreover, CTRP9 had no effect on AMP-activated protein kinase phosphorylation in ADSCs ( Figure 4E and F) , whereas the same CTRP9 concentration activates AMPactivated protein kinase in an AdipoR1-dependent fashion in cardiomyocytes and endothelial cells. 12, 22 These results suggest that a novel, unidentified receptor exists in ADSCs mediating the effects of CTRP9.
To identify the CTRP9 receptor(s) of ADSCs, several discovery-driven approaches were undertaken. Because the heart expresses the greatest levels of CTRP9, CTRP9-binding partner proteins in cardiac tissue samples were immunoprecipitated by anti-CTRP9 antibody. Irrelevant Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. ADSC indicates adipose-derived mesenchymal stem cell; AMPK, adenosine monophosphate -activated protein kinase; CTRP9, C1q/tumor necrosis factor-related protein-9; DMSO, dimethyl sulfoxide; ERK, extracellular regulated protein kinases; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; HO-1, hemeoxygenase 1; MMP-9, matrix metallopeptidase 9; Prdx1, peroxiredoxin 1; Sod-2, manganese superoxide dismutase 2; and Sod-3, extracellular superoxide dismutase 3.
immunoglobulin G immunoprecipitation served as a negative control. After electrophoresis, silver staining was performed. Differential spots between irrelevant immunoglobulin G and anti-CTRP9 antibody were analyzed by mass spectrometry (Figure X in the online-only Data Supplement). Mass spectrometry analysis identified 8 membrane proteins coimmunoprecipitating with CTRP9 (Table II in the online-only Data Supplement). Because T-cadherin is a binding protein for adiponectin 23, 24 and CTRP9 is a highly conserved adiponectin paralog, we reasoned that N-cadherin might be a potential CTRP9 receptor of ADSCs. .01 vs. DMSO+gCTRP9. D and E, ADSCs aoptosis and death were determined by caspase-3 activity (D) (n=4) and LDH release (E) (n=12). Data are mean±SEM. *P<0.05. Statistical significance of (C) was determined with 2-way ANOVA followed by Bonferroni post hoc test. Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. ADSC indicates adipose-derived mesenchymal stem cell; CTRP9, C1q/tumor necrosis factor-related protein-9; DMSO, dimethyl sulfoxide; ERK, extracellular regulated protein kinases; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; LDH, lactic dehydrogenase; MMP-9, matrix metallopeptidase 9; and O.D., optical density.
To obtain direct evidence supporting this notion, we performed several additional experiments. First, immunocytochemistry demonstrated colocalization of CTRP9 and N-cadherin in the cell membrane of CTRP9-treated ADSCs ( Figure 7A ). Second, ADSCs were treated with 5 µg/mL fCTRP9 or 2 µg/mL gCTRP9 for 30 minutes. Cells were harvested and homogenized, and samples were immunoprecipitated with antibody against CTRP9, followed by immunoblot with antibody against N-cadherin. A band representing N-cadherin is clearly visible in samples immunoprecipitated with anti-CTRP9 antibody ( Figure 7B) . Third, to eliminate the influence of endogenous CTRP9, ADSCs were treated with flag-fCTRP9, and samples were immunoprecipitated with antiflag antibody. N-cadherin is coimmunoprecipitated with antiflag antibody ( Figure 7C ). Fourth, to determine whether CTRP9 directly or indirectly interacts with N-cadherin, human recombinant CTRP9 and human recombinant Ncadherin were incubated in a cell-free system. Samples were immunoprecipitated with antibody against CTRP9 and immunoblotted with antibody against N-cadherin. The band representing N-cadherin was clearly detected in the CTRP9+N-cadherin sample ( Figure 7C , Right) but not in the lysis buffer ( Figure 7C , Left) and was immu- +gCTRP9. Statistical significance of (B) was determined with unpaired Student t test. Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. ADSC indicates adipose-derived mesenchymal stem cell; CTRP9, C1q/tumor necrosis factor-related protein-9; DAPI, 4',6-diamidino-2-phenylindole; ERK, extracellular regulated protein kinases; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; HO-1, hemeoxygenase 1; LDH, lactic dehydrogenase; Nrf2, nuclear factor erythroid-derived 2-like 2; Prdx1, peroxiredoxin 1; scNrf2, Nrf2 scramble RNA; siNrf2, Nrf2 short-interfering RNA; Sod-2, manganese superoxide dismutase 2; and Sod-3, extracellular superoxide dismutase 3. noprecipitated with antibody against CTRP9 ( Figure 7D) . Finally, to clarify whether the CTRP9/N-cadherin interaction mediates CTRP9 biological function in ADSCs, N-cadherin-blocking peptide ( Figure XIA A, Coimmunofluorescent staining of CTRP9 (green) and N-cadherin (red) in ADSCs. ADSCs were treated with 2 µg/mL gCTRP9 for 30 minutes before fixation. B, Coimmunoprecipitation (Co-IP) and immunoblot (IB) analysis of N-cadherin with his-gCTRP9 and his-fCTRP9 in ADSCs. ADSCs were treated with vehicle, his-gCTRP9 (2 µg/mL), or his-fCTRP9 (5 µg/mL) for 30 minutes before homogenization. C, Co-IP and IB analysis of N-cadherin with flag-fCTRP9 in ADSCs. ADSCs were treated with vehicle or flagfCTRP9 (5 µg/mL) for 30 minutes before homogenization. D, Co-IP and IB analysis of N-cadherin with CTRP9 in cell-free tubes. E through G, gCTRP9-promoted ADSCs proliferation (E) (n=8) and migration (F1, F2, G1, and G2) (n=4) were significantly inhibited by N-cadherin siRNA and N-cadherin-blocking antibody. N-cadherin-blocking antibody (5 µg/mL) was administered 2 hours before gCTRP9 treatment. Data are mean±SEM. ## P<0.01 vs. scN-cad+vehicle; ΦΦ P<0.01 vs. scN-cad+gCTRP9. Statistical significance of (E) was determined with 2-way ANOVA followed by Bonferroni post hoc test. Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. ADSC indicates adipose-derived mesenchymal stem cell; CTRP9, C1q/tumor necrosis factor-related protein-9; DAPI, 4',6-diamidino-2-phenylindole; flag-fCTRP9, flag labeled full-length CTRP9; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; his-fCTRP9, histidine labeled full-length CTRP9; his-gCTRP9, histidine labeled globular CTRP9; hrCTRP9, human recombinant CTRP9; hrN-cadherin, human recombinant N-cadherin; O.D., optical density; scN-cad, N-cadherin scramble RNA; siN-cad, N-cadherin siRNA; and siRNA, short-interfering RNA.
The previous results demonstrate that CTRP9 promotes ADSCs survival via CTRP9-N-Cadherin-ERK-Nrf2-Dependent Sod-3 signaling. However, CTRP9 fails to promote cardiogenic differentiation of ADSCs and therefore cannot be responsible for the CTRP9/ADSCs synergistic cardioprotective effect. We performed in vitro experiments to determine whether gCTRP9 directly promotes ADSCs' protective effects on cardiomyocytes. Neonatal mouse ventricular cardiomyocytes were treated with fresh medium, CM of ADSCs pretreated with vehicle (veh-CM), or CM of ADSCs pretreated with gCTRP9 (gC-CM, gCTRP9-free; see METHODS section for details). The effect of these different mediums on 3-morpholinosydnonimine (SIN-1)-induced cardiomyocyte apoptosis was determined. 25 Treatment of neonatal mouse ventricular cardiomyocytes with 1 mM SIN-1 for 6 hours caused significant apoptosis, evidenced by increased TUNEL-positive nuclei and cleaved caspase-3 levels ( Figure 8A-C) . Compared with fresh medium, veh-CM moderately decreased TUNEL-positive nuclei and cleaved caspase-3 expression in cardiomyocytes (P<0.05 versus SIN-1+fresh medium; Figure 8A -C). Cardiomyocyte apoptosis was further decreased by gC-CM (P<0.05 or P<0.01 versus SIN-1+veh-CM). These results suggest that gCTRP9 augments secretion of antiapoptotic ADSCs paracrine factors protective of cardiomyocytes.
To determine the molecules present in CM from CTRP9-pretreated ADSCs responsible for cardiomyocyte protection, the levels of 5 molecules upregulated by CTRP9 were determined in CM. No significant difference in total protein concentration between veh-CM and gC-CM was observed ( Figure XIV in the online-only Data Supplement). Sod-2, HO-1, and Prdx1 were undetectable in either veh-CM or gC-CM. However, compared with veh-CM, MMP-9 and Sod-3 were significantly increased >4-fold and >2-fold in gC-CM, respectively ( Figure 8D , Figure VID -F in the online-only Data Supplement). Furthermore, ERK1/2 inhibition with U0126, as well as N-cadherin knockdown or N-cadherin-blocking peptide, completely blocked gCTRP9-induced extracellular secretion of MMP-9 and Sod-3 ( Figure 8E , Figure  XV in the online-only Data Supplement).
To determine the involvement of MMP-9, Sod-3, or both in ADSC-mediated cardiomyocyte protection, the effect of MMP-9-blocking antibody or Sod-3-blocking antibody pretreatment on gC-CM-mediated cardiomyocyte protection was determined. Pretreatment with Sod-3-blocking antibody but not MMP-9-blocking antibody abolished the protective effect of gC-CM against SIN-1-induced cardiomyocyte apoptosis ( Figure 8F ). We also compared the Sod-3 level in peri-infarcted heart tissue 1 day after MI (a time point at which a significant amount of injected ADSCs remain visible). No differences were found among sham, MI+vehicle, or MI+gCTRP9 groups. Compared with MI+vehicle, Sod-3 was slightly increased by ADSC (P>0.05). It is important to note that ADSC+gCTRP9 further increased Sod-3 protein expression compared with ADSC alone (P<0.05; Figure IVE in the online-only Data Supplement). Collectively, these data suggest that CTRP9 stimulates Sod-3 secretion by ADSCs via N-cadherin/ERK/Nrf2 signaling, protecting cardiomyocytes from oxidative stress-induced cell death.
CTRP9 Differentially Regulates MMP-9 Expression in ADSCs and Cardiomyocytes and Inhibits Leukocyte Accumulation in the Peri-Infarct Region
MMP-9 overexpression in the heart after MI promotes cardiac rupture and is thereby deleterious. 26 However, our in vitro experiment demonstrated that gCTRP9 significantly increases MMP-9 expression/activation in ADSCs but reduced cardiac rupture and protected the heart when administered in vivo. To clarify the underlying mechanism(s) for these seemingly contradictory results, 3 additional experiments were performed. First, the effect of in vivo administration of gCTRP9, ADSCs, and their combination on MMP-9 expression in the peri-infarct area was determined. Consistent with previous reported results, MMP-9 was significantly increased (>10 fold) 1 day after MI. ADSC treatment did not significantly alter MMP-9 levels. However, treatment with either gCTRP9 alone or its combination with ADSCs significantly decreased MMP-9 levels in the peri-infarct area ( Figure IVE in the online-only Data Supplement). Second, the effect of CTRP9 on MMP-9 expression levels in cultured neonatal mouse ventricular cardiomyocytes was determined. Both gCTRP9 and fCTRP9 significantly decreased MMP-9 levels in cardiomyocytes ( Figure IVF in the online-only Data Supplement), an effect opposite that observed in ADSCs. Because cardiomyocytes are the predominant cell type in the heart, the inhibitory effect of gCTRP9 on cardiomyocyte MMP-9 expression masked the stimulatory effect of ADSCs on MMP-9 expression. A net inhibitory effect was observed. Third, the effect of gCTRP9, ADSCs, and their combination on leukocyte accumulation in the peri-infarct region was determined. As illustrated in Figure XVI + leukocyte infiltration in the heart after MI. Because inflammatory cells are the main/ major source of MMPs, 27 the reduction of leukocyte accumulation by gCTRP9 and gCTRP9/ADSC will reduce MMPs activity in the peri-infarct region. Taken together, these results suggest that the MMP-9 stimulatory effect of CTRP9 on ADSCs may promote ADSC migration and proliferation. However, CTRP9's inhibitory effect on cardiomyocyte MMP-9 expression, in combination with its strong anti-inflammatory actions, results in an overall MMPs level reduction in the peri-infarct region, reducing cardiac rupture and protecting the heart. A and B, Representative images and quantification of TUNEL-positive NMVCs subjected to 1 mM SIN-1 for 6 hours (n=6). C, Western blot analysis for cleaved caspase-3 in NMVCs. FM, veh-CM, or gC-CM was treated 15 minutes before SIN-1 administration. D, Western blots and quantification of MMP-9 and Sod-3 protein expression in ADSCs CM (n=4-5). E, Western blots and quantification of MMP-9 and Sod-3 in CM demonstrated that U0126, an ERK1/2 activation inhibitor, blocked gCTRP9-induced increased MMP-9 and Sod-3 secretion. U0126 (10 µM) administered 2 hours before gCTRP9 treatment (n=4-5). F, NMVCs apoptosis was determined by cleaved caspase-3 expression. gC-CM was mixed with MMP-9 antibody (5 µg/mL) or Sod-3 antibody (5 µg/mL) 60 minutes before gC-CM treatment. Data are mean±SEM. *P<0.05; **P<0.01. Statistical significance of (D) was determined with unpaired Student t test. Other data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. ADSC indicates adipose-derived mesenchymal stem cell; CM, conditioned medium; CTRP9, C1q/tumor necrosis factor-related protein-9; ERK, extracellular regulated protein kinases; FM, fresh medium; gC-CM, conditioned medium from globular domain isoform of C1q/tumor necrosis factor-related protein-9-pretreated adipose-derived mesenchymal stem cell; gCTRP9, globular domain isoform of C1q/tumor necrosis factor-related protein-9; MMP-9, matrix metallopeptidase 9; NMVC, neonatal mouse ventricular cardiomyocyte; Nrf2, nuclear factor erythroid-derived 2-like 2; SIN-1, 3-morpholinosydnonimine; Sod-3, extracellular superoxide dismutase 3; TUNEL, transferase-mediated dUTP nick-end labeling; and veh-CM, vehicle conditioned medium.
DISCUSSION
Stem cell therapy for the repair of damaged myocardium has evolved into a promising treatment for ischemic heart disease. MSC-based therapy, originating from bone marrow, adipose tissue, or umbilical cord cells, continues to gain consent and appeal because of the large body of preclinical evidence supporting higher paracrine cardioreparative potential. 4 However, the poor survival of donated stem cells and failure of stem cell engraftment in the damaged organ occurs within the first days after delivery, posing a significant challenge in the field. 1 A complete understanding of the mechanisms enhancing MSC migration and survival in the microenvironment of the injured myocardium is imperative to improve both MSC repair capacity and therapeutic application.
In the present study, we have made several novel observations. First, we demonstrated that CTRP9 is a critical molecule determining the fate of implanted ADSCs. Specifically, we demonstrated that local CTRP9 levels are markedly reduced after MI. CTRP9 supplementation at a dose recovering local CTRP9 level markedly improved ADSC engraftment, promoted their migration in the ischemic border zone, and facilitated ADSC-mediated cardiac repair after MI. In contrast, CTRP9 KO restricted migration of implanted ADSCs and further accelerated their death. These results indicate that CTRP9 is an important molecule creating a healthy environment for ADSC survival and enhanced ADSC cardioreparative potential.
Second, we have uncovered new cellular and molecular mechanisms directly responsible for the CTRP9 effect on ADSCs. We identified that proliferation/promigration effects of gCTRP9 on ADSCs were mediated by CTRP9-ERK1/2-MMP-9 signaling because these effects were abolished when ERK1/2 or MMP-9 was inhibited genetically or pharmacologically. MMP-9 has a relationship with stem cell and cancer cell proliferation and migration. 28, 29 Promoting MMP-9 expression by gCTRP9 in ADSCs may thus facilitate their migration when implanted in infarcted heart tissue. Moreover, we provided direct evidence that the antiapoptotic/cell survival effect of gCTRP9 on ADSCs was mediated by the CTRP9-ERK1/2-Nrf2-antioxidative protein expression pathway. Four antioxidants downstream of the redox-sensitive transcription factor Nrf2 20, 21, 30 (including Sod-2, Sod-3, HO-1, and Prdx1) were significantly increased by gCTRP9 in ADSCs. ERK1/2 or Nrf2 knockdown blocked gCTRP9-induced antioxidant protein expression and abolished its antiapoptotic/cell survival effect. These results further support our hypothesis that CTRP9 creates a microenvironment suitable for ADSC survival and migration.
Third, we have identified a novel receptor mediating the actions of CTRP9 on ADSCs. Previous results demonstrated that CTRP9 exerts cardio-and vasculoprotective effects at least partially via AdipoR1. [12] [13] [14] 22 However, we demonstrated that CTRP9 activates ERK1/2 and its downstream signaling in ADSCs in an AdipoR1-independent fashion. Using several techniques, we successfully identified N-cadherin (also known as Cadherin-2, neural cadherin, or CD325) as the specific receptor for CTRP9 acting on ADSCs. N-cadherin is a member of the cell surface glycoproteins mediating calcium-dependent adhesion. 31 Beyond its function in cell-cell adhesion, Ncadherin plays roles in differentiation, migration, invasion, and signal transduction. 32, 33 N-cadherin is a cell surface marker of MSCs, but its downstream signaling in MSCs is largely unknown. In the present study, we revealed that CTRP9 colocalizes and directly interacts with N-cadherin in ADSCs. In agreement with previous reports that ERK1/2 activation is increased when N-cadherin is overexpressed in human umbilical cord bloodderived MSCs and mouse tumor cells, 33, 34 our results demonstrate that CTRP9 activation of ERK1/2-MMP-9 and ERK1/2-Nrf2-antioxidant signaling was abolished by N-cadherin siRNA and blocking antibody.
Finally, we have identified the molecule secreted by CTRP9-stimulated ADSCs that promotes cardiomyocyte survival. Stem cell transplantation for the treatment of cardiac disease is predicated on the hypothesis that such cells engraft, differentiate, and replace damaged cardiac tissue or secrete factors reducing tissue injury or enhancing tissue repair. 35 Among many characteristics, direct transdifferentiation and paracrine effector release are the 2 most important mechanisms by which implanted stem cells protect the heart. 36 We provide no evidence in the present study that CTRP9 manipulates cardiogenic, vasculogenic, or fibrogenic differentiation of ADSCs ( Figure V in the online-only Data Supplement). This finding suggests that CTRP9 does not protect via direct transdifferentiation. However, the CM from CTRP9-pretreated ADSCs exerted potent protection against SIN-1-induced cardiomyocytes apoptosis, suggesting that CTRP9 induced the release of antiapoptotic factors from ADSCs. Analysis of MMP-9 and the 4 antioxidants mentioned earlier (Sod-2, Sod-3, HO-1, and Prdx1) revealed that CTRP9 significantly increased MMP-9 and Sod-3 in the CM of ADSCs, which was abolished by ERK1/2 activation inhibitor and N-cadherin knockdown/ blocking antibody. However, the protective properties of CM from CTRP9-pretreated ADSCs on cardiomyocytes were abolished by Sod-3 neutralizing antibody but not by MMP-9 neutralizing antibody. These results demonstrate that CTRP9/N-cadherin/ERK/Nrf2-dependent Sod-3 secretion is responsible for CTRP9-enhanced ADSCs-mediated cardiomyocyte protection. Although ADSCs may not be the best cell type conducive for cardiac regeneration, ADSCs carry prominent advantage as a rich cellular source with prominent clinical applications.
In summary, we identify CTRP9 as a novel cardiokine regulating MSC engraftment in the infarcted heart via 3 major mechanisms. First, CTRP9 promotes ADSC survival by N-cadherin/ERK/Nrf2 signaling and subsequent upregulation of multiple antioxidative proteins. Second, CTRP9 promotes ADSC proliferation/migration via N-cadherin/ERK signaling and subsequent MMP-9 upregulation. Finally, CTRP9 stimulates ADSC Sod-3 production and secretion, protecting cardiomyocytes against oxidative stress-induced cell death. These results suggest that molecular interventions preserving CTRP9 production or exogenous CTRP9 supplementation may create a healthy microenvironment promoting stem cell survival and optimizing their cardioprotective effect against ischemic cardiac injury.
Limitations
Three limitations exist in the current study. First, cardiac dysfunction was determined by echocardiography at the end of the observation period on surviving animals. Serial echocardiography may have provided more information regarding CTRP9-mediated cardioprotection during the remodeling period after MI. Second, we utilized short-axis M-mode echocardiography to analyze cardiac function after MI instead of longitudinal echocardiographic analysis, which is preferred over M mode for MI models. Third, although we observed that the gCTRP9+ADSC treatment caused a sharp reduction of LV rupture, the translational value of antirupture effect of gCTRP9+ADSC is somewhat limited, as LV rupture is not a frequent complication of MI in modern cardiology. However, we provided clear data demonstrating that gCTRP9+ADSC exerted synergistic protection against cardiac dysfunction after MI, an effect that is of great clinical significance.
